Verfora will take over the distribution of Boiron products in Switzerland from 1 October 2022
Press release, Wednesday, 29 June 2022
Boiron is one of the world’s leading manufacturers and distributors of homeopathic medicines. The company specialises in homeopathic medications with indications, as well as offering a range of individual homeopathic remedies. Its best-known brand in Switzerland is Oscillococcinum®.
The Boiron range fits seamlessly into the existing complementary medicine portfolio of Verfora and its subsidiary Spagyros, and significantly strengthens its presence in the homeopathy segment.
Boiron products generate sales of around CHF 9 million at retail prices in Switzerland1).
It is planned that Boiron employees will be transferred to the Verfora organisation.
Both parties are certain that together they will be able to make even better use of each other’s strengths, and that a partnership encompassing a wide range of products from a single source will also offer interesting added value for specialist retailers and patients alike.
Boiron will benefit from Verfora’s broad and established market coverage, particularly in German-speaking Switzerland, while Verfora will gain access to an exciting product portfolio with an innova-tion pipeline and a wide range of training expertise in homeopathy.
Another important reason for the cooperation is the recognition that Boiron and Verfora share the same values and are both interested in a long-term partnership.
1) IQVIA APO/DRO sell-out CHF MAT April 2022

For further information
Media Relations Galenica
Patrick Fehlmann
Business Partner Corporate Communications
Tel. +41 58 852 85 69
E-mail: media@galenica.com
Investor Relations Galenica
Julian Fiessinger
Head of IR & Corporate Finance
Tel. +41 58 852 85 37
E-mail: investors@galenica.com
Media Relations Boiron
Emeline Guiraud-Boisson
Resp. Contenus et Relations médias
Tel. +33 6 77 48 87 70
E-mail: emeline.guiraud-boisson@boiron.fr
Other press releases
Galenica Group half-year results 2022
Ad hoc announcement pursuant to Art. 53 LR, Tuesday, 9 August 2022
Galenica expands its digital offering in the B2B segment
Press release, Tuesday, 12 July 2022
Galenica takes a stake in the Well digital health platform
Press release, Tuesday, 7 June 2022
Contact
Galenica Ltd.
3027 Bern
Tel. +41 58 852 85 17
Mobile +41 79 371 77 24
Fax +41 58 852 85 58